Mast Cell Activation Syndrome (MCAS): Root Causes, Symptoms & Nutritional Support

Mast cell activation syndrome (MCAS) is one of the most underdiagnosed and misunderstood conditions in modern medicine. Patients with MCAS experience recurrent, multisystem symptoms — affecting the skin, gut, cardiovascular system, respiratory tract, and nervous system — that seem unrelated and defy conventional diagnosis. They are often told their symptoms are anxiety, hypochondria, or medically unexplained, while their mast cells are quietly releasing a storm of inflammatory mediators in response to triggers that most people tolerate without difficulty. This article explains what MCAS is, why it develops, and the most evidence-informed nutritional and lifestyle strategies for stabilizing mast cells and reducing the burden of reactions.

What Are Mast Cells?

Mast cells are immune cells found in virtually every tissue of the body, with the highest concentrations in the skin, gut lining, respiratory tract, and around blood vessels and nerves. They are sentinel cells of the innate immune system — first responders to infection, injury, and environmental threats. When activated, mast cells degranulate, releasing over 200 bioactive mediators including histamine, tryptase, prostaglandins, leukotrienes, cytokines (IL-4, IL-6, TNF-alpha), and heparin. These mediators drive inflammation, increase vascular permeability, stimulate nerves, and coordinate immune responses.

In healthy individuals, mast cell activation is tightly regulated and proportionate to the threat. In MCAS, mast cells are inappropriately activated — releasing mediators in response to triggers that should not provoke a significant immune response, or releasing them spontaneously without any identifiable trigger.

What Is MCAS?

Mast cell activation syndrome is defined by three criteria: (1) recurrent symptoms consistent with mast cell mediator release affecting two or more organ systems; (2) elevation of mast cell mediator markers during symptomatic episodes (serum tryptase, urinary histamine metabolites, prostaglandin D2, or leukotriene E4); and (3) response to mast cell-targeted therapies (antihistamines, mast cell stabilizers). MCAS is distinct from mastocytosis (a clonal mast cell disorder) and from simple allergic reactions, though it shares features with both.

MCAS is increasingly recognized as a common underlying condition in patients with fibromyalgia, chronic fatigue syndrome/ME-CFS, POTS, hypermobile Ehlers-Danlos syndrome (hEDS), long COVID, and interstitial cystitis — conditions that frequently co-occur and share overlapping immune and autonomic dysregulation. Estimates suggest MCAS may affect 14 to 17% of the general population, though most cases remain undiagnosed.

Symptoms of MCAS

MCAS symptoms are characteristically multisystem, episodic, and variable — they can shift from day to day and are often triggered by identifiable exposures. Common symptom patterns include:

Skin: flushing, hives (urticaria), angioedema, dermatographism (skin writing), itching, rashes

Gastrointestinal: nausea, vomiting, abdominal cramping, diarrhea, bloating, reflux, difficulty swallowing

Cardiovascular: palpitations, tachycardia, low blood pressure, near-syncope or syncope, chest pain

Respiratory: nasal congestion, rhinorrhea, wheezing, shortness of breath, throat tightening

Neurological: brain fog, headaches, anxiety, depression, peripheral neuropathy, tinnitus

Musculoskeletal: joint pain, muscle pain, fatigue

The episodic and multisystem nature of MCAS — combined with normal routine lab work — is why patients are so frequently dismissed or misdiagnosed.

Root Causes and Triggers

Genetic Factors

Many MCAS patients have genetic variants affecting mast cell signaling pathways, histamine metabolism (DAO enzyme deficiency, HNMT variants), or connective tissue (hEDS-associated variants). These genetic factors lower the threshold for mast cell activation and impair the body's ability to break down histamine and other mediators.

Gut Dysbiosis and Intestinal Permeability

The gut contains the largest concentration of mast cells in the body, and gut dysbiosis directly activates intestinal mast cells through pattern recognition receptors. Bacterial endotoxins (LPS), Candida overgrowth, and SIBO are potent mast cell activators. Intestinal permeability allows these triggers to reach mast cells continuously, maintaining a state of chronic low-grade activation. Healing the gut is therefore foundational to MCAS management.

Infections and Post-Infectious Triggers

Viral infections — particularly EBV, COVID-19, and herpes viruses — can trigger or dramatically worsen MCAS. Long COVID is now recognized as a major driver of new-onset MCAS, with mast cell activation implicated in the pathophysiology of fatigue, brain fog, cardiovascular symptoms, and multi-system inflammation in long COVID patients. Lyme disease and its co-infections are also significant MCAS triggers.

Toxic and Environmental Triggers

Mold and mycotoxins are among the most potent mast cell activators — MCAS and CIRS (chronic inflammatory response syndrome from mold) frequently co-occur. Heavy metals, pesticides, fragrances, and volatile organic compounds (VOCs) can all trigger mast cell degranulation in sensitized individuals. Reducing environmental toxic burden is a critical component of MCAS management.

Hormonal Factors

Estrogen is a potent mast cell activator — it upregulates mast cell histamine release and downregulates DAO (the enzyme that breaks down histamine). This explains why MCAS symptoms often worsen premenstrually, during perimenopause, and with estrogen-containing medications. Progesterone, conversely, tends to stabilize mast cells. Hormonal balance is an important consideration in MCAS management, particularly in women.

Common MCAS Triggers

Individual triggers vary widely, but the most commonly reported include: high-histamine foods (fermented foods, aged cheeses, alcohol, vinegar, processed meats, leftovers), heat, cold, exercise, stress, fragrances and chemicals, medications (NSAIDs, opioids, contrast dye, certain antibiotics), insect stings, infections, hormonal fluctuations, and EMF exposure. Identifying and reducing personal triggers through a symptom diary is an essential first step.

Key Nutritional Strategies

Low-Histamine Diet

A low-histamine diet reduces the dietary histamine load, giving the body's histamine-degrading enzymes (DAO and HNMT) a better chance of keeping up with demand. High-histamine foods to minimize or avoid include: fermented foods (sauerkraut, kimchi, kefir, kombucha, yogurt), aged cheeses, cured and processed meats, alcohol (especially wine and beer), vinegar and vinegar-containing foods, canned fish, leftovers (histamine increases as food ages), tomatoes, spinach, eggplant, avocado, and strawberries. Fresh, unprocessed foods prepared and eaten immediately are the lowest-histamine options. Note: the low-histamine diet is a therapeutic tool, not a permanent lifestyle — the goal is to reduce the total histamine load while addressing root causes.

Quercetin

Quercetin is the most evidence-backed natural mast cell stabilizer. It inhibits mast cell degranulation, blocks histamine release, reduces IL-6 and TNF-alpha production, and stabilizes mast cell membranes. Multiple in vitro and animal studies have confirmed quercetin's mast cell-stabilizing effects, and it is widely used clinically in MCAS management. Food sources: capers (the richest source), red onions, apples, berries, and green tea. Supplement dose: 500–1,000 mg twice daily, ideally as a bioavailable form (quercetin phytosome or with bromelain). Take 20–30 minutes before meals for best effect.

Vitamin C

Vitamin C is a natural antihistamine — it degrades histamine directly and supports DAO enzyme activity. It also stabilizes mast cell membranes and reduces oxidative stress from mast cell mediator release. Dose: 1,000–2,000 mg/day in divided doses (buffered or liposomal forms are better tolerated at higher doses). Note: some MCAS patients react to corn-derived vitamin C — choose non-corn-sourced ascorbic acid if sensitivity is suspected.

DAO Enzyme Supplementation

Diamine oxidase (DAO) is the primary enzyme responsible for breaking down ingested histamine in the gut. DAO deficiency — whether genetic or acquired (through gut damage, dysbiosis, or nutrient deficiencies) — allows dietary histamine to accumulate and trigger systemic reactions. DAO enzyme supplements taken before meals can significantly reduce histamine-related symptoms in DAO-deficient individuals. Cofactors for DAO activity include vitamin B6 (P5P form), copper, and vitamin C.

Luteolin

Luteolin is a flavonoid with potent mast cell-stabilizing and anti-neuroinflammatory properties. It inhibits IgE-mediated mast cell activation, reduces IL-6 and TNF-alpha, and crosses the blood-brain barrier to reduce neuroinflammation — making it particularly relevant for MCAS patients with brain fog and neurological symptoms. Food sources: celery, parsley, thyme, chamomile tea. Supplement dose: 100–400 mg/day.

Probiotics (Carefully Selected)

Gut healing is foundational for MCAS, but probiotic selection requires care — some strains produce histamine (L. casei, L. bulgaricus, L. helveticus) and can worsen symptoms. Histamine-neutral or histamine-degrading strains are preferred: Lactobacillus rhamnosus GG, L. plantarum, L. salivarius, Bifidobacterium infantis, B. longum, and B. breve. Saccharomyces boulardii supports gut barrier integrity and reduces intestinal mast cell activation. Start with low doses and increase slowly.

Magnesium

Magnesium stabilizes mast cell membranes and reduces degranulation. Magnesium deficiency — extremely common in the general population and worsened by stress — lowers the threshold for mast cell activation. Magnesium glycinate (300–400 mg/day) is the preferred form for tolerability. Note: some MCAS patients react to magnesium citrate or oxide — glycinate is generally the best-tolerated form.

Omega-3 Fatty Acids

EPA and DHA reduce prostaglandin D2 and leukotriene production — two major mast cell mediators — and support resolution of mast cell-driven inflammation. Choose a high-quality, triglyceride-form fish oil tested for heavy metals and oxidation. Dose: 2–3 g/day of combined EPA+DHA. Some MCAS patients are sensitive to fish oil — start with a low dose and increase gradually.

Lifestyle Strategies

Trigger identification and avoidance is the cornerstone of MCAS management — keep a detailed symptom and food diary to identify personal patterns. Stress management is critical: the stress response directly activates mast cells through CRH (corticotropin-releasing hormone) and substance P. Mindfulness, breathwork, vagal nerve stimulation (cold exposure, humming, gargling), and adequate sleep all reduce mast cell reactivity. Avoid extreme temperature changes, intense exercise during flares, and fragrance exposure. Air filtration (HEPA + activated carbon) reduces airborne mast cell triggers in the home environment.

Working with Your Healthcare Team

MCAS diagnosis and management benefit from a knowledgeable physician — ideally an allergist/immunologist, mast cell specialist, or integrative medicine practitioner familiar with MCAS. Conventional treatment includes H1 antihistamines (cetirizine, loratadine), H2 antihistamines (famotidine), mast cell stabilizers (cromolyn sodium, ketotifen), and leukotriene inhibitors (montelukast). These medications can be life-changing for MCAS patients and work synergistically with nutritional interventions. Addressing root causes — gut dysbiosis, infections, mold exposure, hormonal imbalance — is essential for long-term improvement rather than indefinite symptom management.

Related Articles

• Histamine Intolerance — The Overlooked Driver of Allergies, Headaches & Gut Issues
• Leaky Gut (Intestinal Permeability) — Causes, Testing & Repair Protocols
• Mold Illness / CIRS
• Long COVID: Symptoms, Root Causes & Recovery

References

1. Afrin LB, et al. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2016;9(1):115.
2. Theoharides TC, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822(1):21-33.
3. Weinstock LB, et al. Mast cell activation syndrome: a primer for the gastroenterologist. Dig Dis Sci. 2021;66(4):965-982.
4. Weng Z, et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release. PLOS ONE. 2012;7(3):e33805.
5. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85(5):1185-1196.
6. Tsilioni I, Theoharides TC. Luteolin inhibits mast cell activation. J Allergy Clin Immunol. 2018.
7. Molderings GJ, et al. Mast cell activation disease: a systematic review. J Allergy Clin Immunol Pract. 2021.
8. Frieri M, et al. Mast cell activation syndrome: a review. Curr Allergy Asthma Rep. 2013;13(1):27-32.